Treace Medical Q2 revenue $47.4M (+7% YoY); net loss narrows to $17.4M; FY guidance reaffirmed

TREACE MEDICAL CONCEPTS, INC.

2025-Q2 EPS reported -$0.53 revenue$99,957,000

Revenue $47.4M in Q2 2025, up 7% from $44.5M in Q2 2024.
Net loss $(17.4)M ($(0.28)/share) vs $(21.2)M ($(0.34)/share) a year ago; 18% improvement.
Adjusted EBITDA loss improved 58% to $(3.6)M from $(8.7)M in Q2 2024.
Total liquidity $90.7M as of June 30, 2025 ($69.3M cash plus $21.4M revolver).
Full market release of Nanoplasty, Percuplasty 3D MIS Osteotomy, and SpeedMTP Fusion Systems.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.